MedTrace Logo

Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

NCT04154670 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2024-01-11

No results posted yet for this study

Summary

This study is being conducted in healthy subjects and in subjects with a mild or moderate decrease in GFR (subjects with renal impairment).

Conditions

  • Healthy
  • Renal Insufficiency

Interventions

BIOLOGICAL

MGTA-145

MGTA-145 will be given intravenously

Sponsors & Collaborators

  • Ensoma

    lead INDUSTRY

Principal Investigators

  • Will Savage, MD, PhD · Magenta Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-07
Primary Completion
2020-03-24
Completion
2020-03-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04154670 on ClinicalTrials.gov